The company said that the new patent entitled ‘Pharmaceutical Compositions for Buccal and Pulmonary Application’ increases the number of issued patents related to the company’s buccal drug delivery platform technologies to 161.

Generex chief operating officer said that they are pleased that they continue to establish the inventiveness of the company’s buccal delivery system as there has been relatively little progress over the years in reaching the target of safe and effective oral formulations for macromolecules, including peptides and proteins.

“We are pleased that we continue to receive patents from key markets within which our delivery system can be commercialised with a pipeline of viable applications that will open up other marketplaces for the company,” Perri said.